Fundraising FoxType6 Therapeutics
3 known investors
Find your way into Type6 Therapeutics
Sign up to see every warm intro you have to Type6 Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Type6 Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Type6 Therapeutics is a drug-discovery company developing kinase inhibitors that target the inactive OFF-state of kinases to improve selectivity and durability against cancers that evade existing therapies. Its lead program is a CDK2 inhibitor (CDK2i), with plans to expand into additional kinase targets across the human kinome.
Founders & leadership
AB
Alexander BridgesCo-founder, CSO, VP Chemistry
JO
Jeffrey OhrenCo-founder, VP BiologyHe previously led structural biology research that elucidated the mechanism of the kinase inhibitor trametinib, and has published extensively in protein chemistry and structural biology with a focus on kinase-targeted drug design.
MO
Mihail ObroceaHead of Development
RS
Robert SonsHead of Operations
Investors · 3
Artis Ventureslisted by Artis VenturesSan Francisco · $50K – $25M
How we know: Artis Ventures's portfolio page · Not right? Tell us
BoxOne Ventureslisted by BoxOne VenturesMontréal · $500K
How we know: BoxOne Ventures's portfolio page · the VCSheet dataset · Not right? Tell us
OMX Ventureslisted by OMX VenturesLincolnshire
How we know: the VCSheet dataset · Not right? Tell us
Frequently asked questions
- What does Type6 Therapeutics do?
- Type6 Therapeutics is a drug-discovery company developing kinase inhibitors that target the inactive OFF-state of kinases to improve selectivity and durability against cancers that evade existing therapies. Its lead program is a CDK2 inhibitor (CDK2i), with plans to expand into additional kinase targets across the human kinome.
- Who founded Type6 Therapeutics?
- Type6 Therapeutics was founded by Gert Kiss, Alexander Bridges, Jeffrey Ohren.
- Who are Type6 Therapeutics's investors?
- Type6 Therapeutics's investors include Artis Ventures, BoxOne Ventures, OMX Ventures.